This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Osiris Therapeutics Takes a Bumpy Ride

The original design of the Prochymal phase II study called for a control arm to be enrolled, with patients receiving steroids alone that could have been used to more accurately assess Prochymal's efficacy. Response in the original study also called for a measurement at day 42.

But in 2005, right before the phase II study was to start, Osiris altered the study design to eliminate the control group and shorten the efficacy endpoint to measure response at day 28. The changes were made so the study could be run more quickly, the company says. That might be true, but it also lowered the bar by which Prochymal could be deemed a success.

This may also explain why the ongoing phase III trial is only enrolling GVHD patients who no longer respond to steroids (a sicker patient population than enrolled the phase II study.) Osiris is enrolling 240 patients in this phase III study, split between patients getting Prochymal injection and a placebo.

If positive, the company plans to seek FDA approval. Enrollment in the trial is expected to finish up this summer, with data ready for release by the end of the year. Treatment of steroid-refractory GVHD is an unmet medical need, but one with small commercial potential of around $30 million per year.

Investors are right to be excited by companies developing cutting-edge stem-cell therapies. But the path to innovative new cures and treatments for life-threatening diseases is not going to be smooth, as Tuesday's disappointing news from Osiris illustrates. And while the stem-cell headlines may look sensational, the details are what will ultimately count most.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OSIR $10.28 -1.72%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%
TSLA $229.64 5.22%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs